Log in
Enquire now

List of Tetra Therapeutics patents

List of Tetra Therapeutics patents
List of Calypto Design Systems patents
List of Transmeta patents
List of University College Dublin patents
List of ecommerce companies in Switzerland
List of companies in LAB Ventures's investment portfolio
Patents where
Current Assignee
Name
is
Tetra TherapeuticsTetra Therapeutics
Name
Description
Patent Applicant
Current Assignee
Inventor
Patent Jurisdiction
Patent Number
Date of Patent
‌
US Patent 11401286 Heteroaryl inhibitors of PDE4

Patent 11401286 was granted and assigned to Tetra Therapeutics on August, 2022 by the United States Patent and Trademark Office.

Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
11401286
August 2, 2022
‌
US Patent 10364258 Heteroaryl inhibitors of PDE4

Patent 10364258 was granted and assigned to Tetra Therapeutics on July, 2019 by the United States Patent and Trademark Office.

Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
10364258
July 30, 2019
‌
US Patent 10093686 Heteroaryl inhibitors of PDE4

Patent 10093686 was granted and assigned to Tetra Therapeutics on October, 2018 by the United States Patent and Trademark Office.

Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
10093686
October 9, 2018
‌
US Patent 11028050 Salts and polymorphs of a PDE4 inhibitor

Patent 11028050 was granted and assigned to Tetra Therapeutics on June, 2021 by the United States Patent and Trademark Office.

Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
11028050
June 8, 2021
‌
US Patent 9777024 Heteroaryl inhibitors of PDE4

Patent 9777024 was granted and assigned to Tetra Therapeutics on October, 2017 by the United States Patent and Trademark Office.

Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
9777024
October 3, 2017
‌
US Patent 11104660 PDE4D inhibitors

Patent 11104660 was granted and assigned to Tetra Therapeutics on August, 2021 by the United States Patent and Trademark Office.

Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
11104660
August 31, 2021
‌
US Patent 10626129 Heteroaryl inhibitors of PDE4

Patent 10626129 was granted and assigned to Tetra Therapeutics on April, 2020 by the United States Patent and Trademark Office.

Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
10626129
April 21, 2020
‌
US Patent 9221843 Heteroaryl inhibitors of PDE4

Patent 9221843 was granted and assigned to Tetra Therapeutics on December, 2015 by the United States Patent and Trademark Office.

Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
9221843
December 29, 2015
‌
US Patent 8865723 Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury

Patent 8865723 was granted and assigned to Tetra Therapeutics on October, 2014 by the United States Patent and Trademark Office.

Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
Tetra Therapeutics
United States Patent and Trademark Office
United States Patent and Trademark Office
8865723
October 21, 2014
9 results
0 selected
9 results
0 selected
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us